Pfizer (PFE) R&D In Process (2021 - 2025)
Historic R&D In Process for Pfizer (PFE) over the last 7 years, with Q3 2025 value amounting to $1.4 billion.
- Pfizer's R&D In Process rose 1059230.77% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 145384.62%. This contributed to the annual value of $108.0 million for FY2024, which is 4432.99% down from last year.
- According to the latest figures from Q3 2025, Pfizer's R&D In Process is $1.4 billion, which was up 1059230.77% from $2.0 million recorded in Q2 2025.
- Over the past 5 years, Pfizer's R&D In Process peaked at $1.4 billion during Q3 2025, and registered a low of $1.0 million during Q3 2022.
- Moreover, its 5-year median value for R&D In Process was $33.0 million (2023), whereas its average is $229.1 million.
- Its R&D In Process has fluctuated over the past 5 years, first crashed by 9954.34% in 2022, then soared by 1059230.77% in 2025.
- Pfizer's R&D In Process (Quarter) stood at $706.0 million in 2021, then fell by 25.78% to $524.0 million in 2022, then plummeted by 86.26% to $72.0 million in 2023, then plummeted by 81.94% to $13.0 million in 2024, then skyrocketed by 10592.31% to $1.4 billion in 2025.
- Its R&D In Process was $1.4 billion in Q3 2025, compared to $2.0 million in Q2 2025 and $9.0 million in Q1 2025.